Respiratory syncytial virus
Start with the big picture
RSV prevention in the source centers on monoclonal antibodies. Palivizumab targets the viral fusion protein and is given monthly during the season to certain high-risk children; nirsevimab is a longer-acting antibody intended to provide season-long protection. Ribavirin, an antiviral that inhibits viral RNA-dependent RNA polymerase, is described for critically ill or immunocompromised patients, with important safety concerns including hemolytic anemia and teratogenicity. Resistance associated with changes in the F protein is uncommon but monitored. The source also distinguishes infant vaccination from maternal vaccination: it notes no licensed RSV vaccine for infants as of 2023, while describing maternal RSVpreF vaccination as a means of passive newborn protection. For most otherwise healthy infants, supportive care remains the first-line approach.
What you'll learn
- Describe how palivizumab and nirsevimab target RSV.
- Identify the high-risk groups described for palivizumab prophylaxis.
- Explain ribavirin’s mechanism and the severe cases in which it may be used.
- Recognize key ribavirin adverse effects and the potential for F-protein resistance.
- Distinguish infant RSV vaccination from maternal vaccination and supportive care.
Continue your study
Work through the complete notes and reinforce the topic with the study tools available in the full lesson.
